BEIJING, Nov. 10 /Xinhua-PRNewswire-FirstCall/ -- Yongye Biotechnology International, Inc. , a leading developer, producer and distributor of nutrients for plants and animals, located in the People's Republic of China, today announced that the Company will present at the upcoming Roth Capital "China Comes to Vegas" conference held on November 19-21, 2008 at the Wynn Hotel in Las Vegas, Nevada.
The Company will be available to meet with analysts and investors during the conference. Participation in the Roth "China Comes to Vegas" conference is by invitation only. For more information about the conference, please visit http://www.roth.com/ or E-mail conference@roth.com .
About Yongye Biotechnology International, Inc.
Yongye Biotechnology International, Inc., headquartered in Beijing, is engaged in the research and development, distribution and sales of fulvic acid based nutrients for plants and animals. The Company's patent pending processes and proprietary formulas allow it to create products that increase crop yields and improve the health of livestock. Its sole operating subsidiary, Yongye Nongfeng Biotechnology Company, Ltd., is located in Inner Mongolia, People's Republic of China. The Company sells its products through distributors and directly to farmers located in ten provinces throughout China.
Safe Harbor Statement
This press release contains certain statements that may include "forward looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the risk factors discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on the SEC's website ( http://www.sec.gov ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
CONTACT: Mr. Larry Gilmore-VP of Corporate Strategy of Yongye
Biotechnology International, Inc., +86-8232-8866 x8880, or
larry.gilmore@gmail.com; or at CCG Investor Relations, Inc., Mr. Crocker
Coulson, President, +1-646-213-1915 (New York), or
crocker.coulson@ccgir.com, for Yongye
Web site: http://www.roth.com/
